Midatech Pharma（纳斯达克股票代码：MTP）vs.Kronos Bio（纳斯达克股票代码：KRON）财务比较

Midatech Pharma (NASDAQ:MTP – Get Rating) and Kronos Bio (NASDAQ:KRON – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Profitability

This table compares Midatech Pharma and Kronos Bio's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Midatech Pharma and Kronos Bio's revenue, earnings per share (EPS) and valuation.

Midatech Pharma has higher revenue and earnings than Kronos Bio.

Volatility and Risk

Midatech Pharma has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Insider & Institutional Ownership

4.2% of Midatech Pharma shares are owned by institutional investors. Comparatively, 63.4% of Kronos Bio shares are owned by institutional investors. 0.3% of Midatech Pharma shares are owned by insiders. Comparatively, 28.2% of Kronos Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Midatech Pharma and Kronos Bio, as reported by MarketBeat.com.

Kronos Bio has a consensus target price of $10.75, indicating a potential upside of 563.58%. Given Kronos Bio's higher probable upside, analysts plainly believe Kronos Bio is more favorable than Midatech Pharma.

Summary

Midatech Pharma beats Kronos Bio on 5 of the 9 factors compared between the two stocks.

About Midatech Pharma

(Get Rating)

Midatech Pharma Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

About Kronos Bio

(Get Rating)

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of entospletinib in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, is a next-generation SYK inhibitor for treatment of autoimmune disease. Kronos Bio, Inc. was incorporated in 2017 and is headquartered in San Mateo, California.

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.